A Randomized Phase II Non-Comparative Study of SB-715992 Given Weekly or Every Three Weeks in Advanced or Metastatic Colorectal Cancer
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Ispinesib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 02 Mar 2015 Biomarkers information updated
- 11 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Oct 2010 Actual end date (September 2010) added as reported by ClinicalTrials.gov.